Indications
Therapeutic Asset Ratings
3,272 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Fludarabine
Thymus Neoplasm
National Cancer Institute (NCI)
P1
CC
(43)
Fluorouracilum
Digestive System Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Fluorouracilum
Appendix Cancer
National Cancer Institute (NCI)
P1
CC
(43)
Grt-C903
Malignant Urinary System Neoplasm
National Cancer Institute (NCI)
P1
CC
(43)
Grt-C903
Metastatic Malignant Neoplasm
National Cancer Institute (NCI)
P1
CC
(43)
Grt-R904
Malignant Urinary System Neoplasm
National Cancer Institute (NCI)
P1
CC
(43)
Grt-R904
Metastatic Malignant Neoplasm
National Cancer Institute (NCI)
P1
CC
(43)
Hcv Dna Vaccine Ino-8000
Hepatitis
National Cancer Institute (NCI)
P1
CC
(43)
Hcv Dna Vaccine Ino-8000
Hepatitis C Virus Infection
National Cancer Institute (NCI)
P1
CC
(43)
Ibrutinib
Primary Effusion Lymphoma
National Cancer Institute (NCI)
P1
CC
(43)
Ibrutinib
Diffuse Large B-Cell Lymphoma Of The Central Nervous System
National Cancer Institute (NCI)
P1
CC
(43)
Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,461-Alanine,462-Alanine,556-Glycine,581-Cysteine,593-Tryptophan), Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 Vh-Ch1 Fragment) Fusion Protein With Peptide (Synthetic 10-Amino Acid Linker) Fusion Protein With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Heavy Chain Vl(.Lambda.)-Ch1-Ch2-Ch3), (222->219''')-Disulfide With Immunoglobulin Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)) And (447->232'')-Disulfide With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Light Chain Vh-Cl(.Kappa.)), (453->228'), (456->231'), (581->351')-Tris(Disulfide) With Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,236-Alanine,237-Alanine,331-Glycine,351-Cysteine,368-Serine,370-Alanine,409-Valine) Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)
High Grade B-Cell Lymphoma With MYC And/ Or BCL2 And/Or BCL6 Rearrangement
National Cancer Institute (NCI)
P1
CC
(43)
Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,461-Alanine,462-Alanine,556-Glycine,581-Cysteine,593-Tryptophan), Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 Vh-Ch1 Fragment) Fusion Protein With Peptide (Synthetic 10-Amino Acid Linker) Fusion Protein With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Heavy Chain Vl(.Lambda.)-Ch1-Ch2-Ch3), (222->219''')-Disulfide With Immunoglobulin Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)) And (447->232'')-Disulfide With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Light Chain Vh-Cl(.Kappa.)), (453->228'), (456->231'), (581->351')-Tris(Disulfide) With Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,236-Alanine,237-Alanine,331-Glycine,351-Cysteine,368-Serine,370-Alanine,409-Valine) Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)
Primary Effusion Lymphoma
National Cancer Institute (NCI)
P1
CC
(43)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
Gliosarcoma
National Cancer Institute (NCI)
P1
CC
(43)
Inalimarev
Pancreatic Acinar Cell Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Inalimarev
Malignant Pancreatic Neoplasm
National Cancer Institute (NCI)
P1
CC
(43)
Ipatasertib
Fallopian Tube Serous Adenocarcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Ipatasertib
Ovarian Serous Adenocarcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Ipatasertib
Primary Peritoneal Serous Adenocarcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Ipatasertib
Fallopian Tube Cancer
National Cancer Institute (NCI)
P1
CC
(43)
Ipilimumab
Autoimmune Disease
National Cancer Institute (NCI)
P1
CC
(43)
Ipilimumab
Crohn Disease
National Cancer Institute (NCI)
P1
CC
(43)
Ipilimumab
Dermatomyositis
National Cancer Institute (NCI)
P1
CC
(43)
Ipilimumab
Inflammatory Bowel Disease
National Cancer Institute (NCI)
P1
CC
(43)
Ipilimumab
Invasive Breast Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Showing 2851 to 2875 of 3,272 assets
Previous
Page 115 of 131
Next
